In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Ng, Teresa I ^a   Krishnan, Preethi ^a   Pilot Matias, Tami ^a   Kati, Warren ^a   Schnell, Gretja ^a   Beyer, Jill ^a   Reisch, Thomas ^a   Lu, Liangjun ^a   Dekhtyar, Tatyana ^a   Irvin, Michelle ^a   Tripathi, Rakesh ^a   Maring, Clarence ^a   Randolph, John T ^a   Wagner, Rolf ^a   Collins, Christine ^a  

^a ABBVIE INC   (United States)

Author keywords

ABT 530; Antiviral activity; HCV; NS5A inhibitor; Pibrentasvir; Resistance

Indexed keywords

ALPHA INTERFERON; GLECAPREVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; PIBRENTASVIR; PROTEINASE INHIBITOR; RIBAVIRIN; ABT-530; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PYRROLIDINE DERIVATIVE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; EC50; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 2A; HEPATITIS C VIRUS GENOTYPE 2B; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3A; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 4A; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 5A; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 6A; HEPATITIS C VIRUS GENOTYPE 6E; HEPATITIS C VIRUS GENOTYPE 6P; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REPLICON; REPLICON CELL; THERAPEUTIC INDEX; WILD TYPE; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; HEPACIVIRUS; HEPATITIS C; TUMOR CELL LINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; HEP G2 CELLS; HEPACIVIRUS; HEPATITIS C; HUMANS; PYRROLIDINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85018189969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02558-16     Document Type: Article

References (50)

1. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. 2015. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77-87. https://doi.org/10.1002/hep.27259.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61(Suppl):S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027.
3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59:318-327. https://doi.org/10.1002/hep.26744.
4. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. 2011. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 31(Suppl 2):S61-S80.
5. Arzumanyan A, Reis HM, Feitelson MA. 2013. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 13:123-135. https://doi.org/10.1038/nrc3449.
6. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. 2012. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308: 2584-2593. https://doi.org/10.1001/jama.2012.144878.
7. Kwong AD. 2014. The HCV revolution did not happen overnight. ACS Med Chem Lett 5:214-220. https://doi.org/10.1021/ml500070q.
8. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. 2016. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36(Suppl 1):47-57. https://doi.org/10.1111/liv.13027.
9. Pawlotsky JM. 2014. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146:1176-1192. https://doi.org/10.1053/j.gastro.2014.03.003.
10. Merck & Co., Inc. 2016. Zepatier (elbasvir and grazoprevir) tablets, for oral use, package insert. Merck & Co., Inc., Whitehouse Station, NJ. https://www.merck.com/product/usa/pi-circulars/z/zepatier/zepatier-pi.pdf.
11. Jacobson IM, Asante-Appiah E, Wong P, Black T, Howe A, Wahl J, Robertson MN, Nguyen B-Y, Shaughnessy M, Hwang P, Barr E, Hazuda D. 2015. Prevalence and impact of baseline NS5A resistance-associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection. Hepatology 62(Suppl 1):1393A-1394A.
12. McPhee F, Hernandez D, Yu F, Ueland J, Monikowski A, Carifa A, Falk P, Wang C, Fridell R, Eley T, Zhou N, Gardiner D. 2013. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology 58:902-911. https://doi.org/10.1002/hep.26388.
13. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. 2014. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 20:2902-2912. https://doi.org/10.3748/wjg.v20.i11.2902.
14. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. 2015. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 62:1623-1632. https://doi.org/10.1002/hep.27934.
15. Macdonald A, Harris M. 2004. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485-2502. https://doi.org/10.1099/vir.0.80204-0.
16. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T, Matsuura Y, Miyamura T, Wakita T, Suzuki T. 2008. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol 82:7964-7976. https://doi.org/10.1128/JVI.00826-08.
17. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, De Micco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM. 2011. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54: 1956-1965. https://doi.org/10.1002/hep.24609.
18. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. 2012. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS- 5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24-31. https://doi.org/10.1016/j.jhep.2011.12.029.
19. Lawitz J, Marbury T, Campbell A, Dumas E, Pilot-Matias T, Krishnan P, Setze C, Xie W, Podsadecki T, Bernstein B, Williams L. 2012. Safety and antiviral activity of ABT-267, a novel NS5A inhibitor, during 3-day monotherapy: first study in HCV genotype-1 (GT1)-infected treatmentnaive subjects. J Hepatol 56(Suppl 2):S469-S470. https://doi.org/10.1016/S0168-8278(12)61198-2.
20. Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee YJ, Gong R, Yu M, Han B, Xu S, Dvory-Sobol H, Perron M, Xu Y, Mo H, Pagratis N, Link JO, Delaney W. 2016. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 60:1847-1853. https://doi.org/10.1128/AAC.02524-15.
21. Cheng G, Yu M, Peng B, Lee YJ, Trejo-Martin A, Gong R, Bush C, Worth A, Nash M, Chan K, Yang H, Beran R, Tian Y, Perry J, Taylor J, Yang C, Paulson M, Delaney W, Link JO. 2013. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier. J Hepatol 58(Suppl 1):S484-S485. https://doi.org/10.1016/S0168-8278(13)61192-7.
22. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, De Goey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979-987. https://doi.org/10.1128/AAC.04226-14.
23. Liu R, Kong R, Mann P, Ingravallo P, Zhai Y, Xia E, Ludmerer S, Kozlowski J, Coburn C. 2012. In vitro resistance analysis of Merck's HCV NS5a inhibitor MK-8742 demonstrates increased potency against clinical resistance variants and improved resistance profile. J Hepatol 56(Suppl 2):S334-S335. https://doi.org/10.1016/S0168-8278(12)60870-8.
24. Wang C, Jia L, O'Boyle DR, II, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA. 2014. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother 58:5155-5163. https://doi.org/10.1128/AAC.02788-14.
25. Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. 2013. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 57:611-613. https://doi.org/10.1128/AAC.01874-12.
26. Zhou N, Han Z, Hartman-Neumann S, De Gray B, Ueland J, Vellucci V, Hernandez D, McPhee F. 2016. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 71: 3495-3505. https://doi.org/10.1093/jac/dkw336.
27. Doehle B, Dvory-Sobol H, Hebner C, Gontcharova V, Chodavarapu K, Ouyang W, Rodriguez-Torres M, Lawitz E, Yang C, McNally J, Link J, Mo H. 2013. Deep sequencing of HCV NS5A from a 3-day study of GS-5816 monotherapy confirms the potency of GS-5816 against pre-existing genotype 1-3 NS5A resistance-associated variants abstr 470. Abstr 64th Annu Meet Am Assoc Study Liver Dis, Washington, DC.
28. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. 2013. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol 57:13-18. https://doi.org/10.1016/j.jcv.2012.12.020.
29. Gane E, Nahass R, Luketic V, Hwang P, Robertson M, Wahl J, Barr E, Haber B. 2015. Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. J Hepatol 62(Suppl 2):S621. https://doi.org/10.1016/S0168-8278(15)30979-X.
30. Gao M. 2013. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 3:514-520. https://doi.org/10.1016/j.coviro.2013.06.014.
31. Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, Di Nubile MJ, Howe AY. 2015. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59:6922-6929. https://doi.org/10.1128/AAC.01390-15.
32. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C. 2015. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:1505-1511. https://doi.org/10.1128/AAC.04619-14.
33. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. 2012. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359-3368. https://doi.org/10.1128/AAC.00054-12.
34. Ng TI, Reisch T, Middleton T, McDaniel K, Kempf D, Lu L, Wang G, Jiang L, Or YS, Pilot-Matias T. 2014. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotype coverage, abstr 636. Abstr 21st Annu Conf Retroviruses Opportunistic Infect, Boston, MA.
35. Wang C, Sun JH, O'Boyle DR, II, Nower P, Valera L, Roberts S, Fridell RA, Gao M. 2013. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother 57:2054-2065. https://doi.org/10.1128/AAC.02494-12.
36. Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E, Miller MD, Mo H. 2013. Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57:6333-6340. https://doi.org/10.1128/AAC.02193-12.
37. Black S, Pak I, Ingravallo P, McMonagle P, Chase R, Shaughnessy M, Hwang P, Haber B, Harrigan PR, Brumme C, Hazuda D, Howe AY. 2015. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with grazoprevir + elbasvir ± ribavirin: the C-WORTHY study, abstr P0891. Abstr 50th Annu Meet Eur Assoc Study Liver, Vienna, Austria.
38. Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, Lovell S, Ng TI, Liu W, Campbell A, Lin CW, Yao B, Kort J. 2016. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother 60:1546-1555. https://doi.org/10.1128/AAC.02264-15.
39. Lawitz E, Freilich B, Link J, German P, Mo H, Han L, Brainard DM, McNally J, Marbury T, Rodriguez-Torres M. 2015. A phase 1, randomized, doseranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 22:1011-1019. https://doi.org/10.1111/jvh.12435.
40. Ng T, Pilot-Matias T, Tripathi R, Schnell G, Reisch T, Beyer J, Dekhtyar T, Asatryan A, Mensa FJ, Campbell AL, Kort J, Collin C. 2015. Analysis of HCV genotype 1 variants detected during monotherapy and combination therapy with next generation HCV direct-acting antiviral agents ABT-493 and ABT-530. Hepatology 62(Suppl S1):558A.
41. Gane E, Lalezari J, Asatryan A, Greenbloom S, Hassanein TI, Ng T, Liu R, Lin C-W, Kort J, Mensa F. 2016. 100% SVR4 and favorable safety of ABT-493 + ABT-530 administered for 12 weeks in non-cirrhotic patients with genotypes 4, 5, or 6 infection (Surveyor-I). Gastroenterology 150(Suppl 1):S1047. https://doi.org/10.1016/S0016-5085(16) 33540-5.
42. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. 2016. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology 151:651-659.e651. https://doi.org/10.1053/j.gastro.2016.07.020.
43. Poordad F, Felizarta F, Wang S, Asatryan A, Hassanein TI, Aguilar H, Lalezari J, Overcash JS, Ng T, Lovell SS, Lin C-W, Kort J, Mensa F. 2016. High SVR rates with the combination of ABT-493 + ABT-530 for 8 weeks in non-cirrhotic patients with HCV genotype 1 or 2 infection. Gastroenterology 150(Suppl 1):S1046-S1047. https://doi.org/10.1016/S0016-5085(16)33537-5.
44. Poordad F, Gordon SC, Asatryan A, Felizarta F, Reindollar RW, Landis C, Fried MW, Bernstein DE, Ng TI, Lin C, Liu R, Kort J, Mensa FJ. 2016. High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the Magellan-I study, abstr GS-11. Abstr 51st Annu Meet Eur Assoc Study Liver, Barcelona, Spain.
45. Dvory-Sobol H, Wyles D, Ouyang W, Chodavarapu K, McNally J, Cheng W, Shafran S, Mangia A, Schwabe C, Miller MD, Mo H. 2015. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol 62(Suppl 2):S221. https://doi.org/10.1016/S0168-8278(15)30073-8.
46. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. 2015. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59:5445-5454. https://doi.org/10.1128/AAC.00998-15.
47. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113. https://doi.org/10.1126/science.285.5424.110.
48. Prichard MN, Shipman C, Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1:9-20.
49. Prichard MN, Aseltine KR, Shipman C, Jr. 1993. MacSynergy II, version 1.0. University of Michigan, Ann Arbor, MI.
50. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540-545. https://doi.org/10.1128/AAC.37.3.540.